Introduction
tumor explants can be cultured, a serious shortcoming of In recent years there has been renewed interest in the use this method is the possible loss of expression of tumorof cancer vaccines to generate tumor-specific systemic associated antigens or major histocompatibility complex immunity.
1 Induction of an antitumor immune response (MHC) class I molecules during the procedure. In an by ectopic cytokine synthesis is one approach which has attempt to circumvent these problems, other options are shown promise in murine tumor models and is now being explored with a desirable goal being to treat being evaluated in human clinical trials. 2 The general tumors in situ. Thus, retroviral producer cells, DNA-lipoprinciple of this strategy is to increase the immunosome complexes and recombinant adenoviruses are being genicity of tumor cells by genetically engineering them to tested as gene delivery systems. 5 A variation of this stratexpress high local concentrations of immunostimulatory egy utilizes cytokine gene-transduced autologous skin cytokines at the tumor site. However, many obstacles fibroblasts. 6 We are investigating an alternative vaccipreclude facile extension of the experimental protocol to nation protocol to treat melanoma patients which the clinical setting. A major limitation, irrespective of the involves peritumoral injections of irradiated autologous availability of a highly efficient gene transfer system, 3,4 is tumor cells admixed with previously characterized, cytothe labor intensity and difficulty in obtaining sufficient kine-secreting allogeneic melanoma cell lines. [7] [8] [9] [10] The quantities of cells from each tumor for ex vivo production rationale for this approach comes from evidence that there are shared melanoma tumor antigens which are recognized by cytolytic T cells in the context of the HLA-essential that the genetically modified melanoma cell constructed which contained this modification. In another version, the double-copy vector format was lines stably express the exogenous cytokine genes at therapeutically relevant levels, a distinct advantage over employed in which the bicistronic nlslacZ-IRES-neo cassette, driven by the human cytomegalovirus immediatestrictly autologous vaccine strategies is that this procedure does not require high-efficiency gene transfer early (hCMV-IE) gene promoter, was introduced into the U3 region of the 3′ LTR. [35] [36] [37] We report here that, methodology.
Retroviral vectors are the most commonly used delivalthough the titer of the nlslacZ double-copy bicistronic vector was lower than the titers of the other vectors ery vehicles in gene therapy applications. [12] [13] [14] Most retroviral vectors are derived from the Moloney murine leukeevaluated, it was correctly transmitted at high frequency to the target melanoma cells and after G418 selection, it mia virus (MoMLV) and utilize the 5′ long terminal repeat (LTR) together with an internal promoter to coexroutinely gave the highest levels of gene expression among the various MSCV-based constructs. Notably, press the therapeutic gene product and a selectable marker. However, MoMLV expression is strongly suphigher stable levels of gene expression were obtained in general than were achieved with a MoMLV-based env pressed in certain cell types and transcriptional inactivation of MoMLV-derived vectors in vivo has been splice acceptor-containing retroviral vector (SAMEN). 34 In preclinical studies with the B-78 murine melanoma observed in some instances. [15] [16] [17] [18] Even if an ex vivo selection step can be employed, the selection strategy does not model, we found that the combination of interleukin-6 (IL-6) and soluble IL-6 receptor was more effective in ensure maintenance of expression of the therapeutic gene in vectors having this double-promoter configuration.
inducing an antitumor response than IL-6 alone. 38 Therefore, with a view towards producing analogous genetiIndeed, a potential difficulty with this design is that selection for expression of the marker gene might actucally modified human melanoma cell lines for development of clinical cancer vaccines and guided by the above ally result in down-regulation of transcription of the gene of interest.
19 One way to overcome this problem is to creresults, we subsequently created MSCV-based doublecopy bicistronic vectors carrying the human IL-6 (hIL-6) ate a bifunctional chimeric protein by fusing the therapeutic gene in-frame with the selectable marker gene. 20 gene and the cDNA encoding a soluble form of the human IL-6 receptor (hsIL-6R), 39 and used these to transThis is not practical, however, when the therapeutic gene product is a secreted protein. Another approach which duce the panel of human melanoma cell lines. In all cases, stable transductants secreting hIL-6/hsIL-6R at levels avoids transcriptional interference involves the use of internal ribosome entry site (IRES) sequences from the 5′-above those that had antitumor effects in the B-78 murine melanoma model were successfully generated. untranslated regions of picornaviruses to create polycistronic transcripts encoding multiple gene products. 21 We previously described the construction of the MSCV
Results
(murine stem cell virus) series of retroviral vectors from the MESV, LN and HMB vector systems. 15 25, 26 Consequently, safety-modified versions of the ure 1. In MSCVnlslacZ, the nlslacZ gene is expressed from the retroviral LTR and the selectable neo marker gene is MSCV backbone were created for gene therapeutics involving human hematopoietic cells. 27 Initial reports of independently expressed from an internal pgk promoter. The bicistronic MINVnlslacZ and MENVnlslacZ vectors high levels of gene expression in human CD34
+ hematopoietic progenitors transduced with MSCV vectors indiuse the MSCV LTR to express the nlslacZ-IRES-neo cassette while nlslacZ-IRES-neo transcription is driven by the cate that the MSCV platform may prove to be of utility for this intended purpose. [28] [29] [30] The finding that MSCV hCMV-IE promoter in DCCMVnlslacZ. The major difference between MINVnlslacZ and MENVnlslacZ is the was capable of directing high-level gene expression in a human hepatoma cell line prompted us to investigate presence of the env splice acceptor in the latter. As a consequence, nlslacZ is expressed from spliced transcripts whether it might also be useful for production of cancer vaccines for the treatment of patients with solid in MENVnlslacZ whereas splicing is not required for translation of the nlslacZ coding region in MINVnlslacZ. tumors. 31, 32 In the present study, we compared expression from a MENVnlslacZ is similar in configuration to the MoMLVbased SAMENnlslacZ vector (see Materials and conventional MSCV vector with that from several MSCVbased derivatives in four human melanoma cell lines. A methods), which was evaluated in parallel. The distinguishing feature of DCCMVnlslacZ, which is an modified E. coli LacZ gene (nlslacZ) encoding ␤-galactosidase and containing a nuclear localization signal was example of a double-copy vector, is that the hCMV-IEnlslacZ-IRES-neo transcriptional unit present in the U3 used as the reporter gene; 33 
blue colony-forming results in the hCMV-IE-nlslacZ-IRES-neo transcriptional unit in the U3 region of 3′ LTR being transferred to the 5′ LTR such that the units per milliliter). As predicted from the bicistronic

DCCMVnlslacZ provirus harbors two copies, one copy in each LTR.
design, comparable titers were obtained for the various vectors when conversion of WM9 target cells to G418 resistance was measured; in contrast, the Neo titer obtained for MSCVnlslacZ (reflecting the transcriptional (DCCMVnlslacZ), followed by selection in G418-supplemented medium. X-gal staining revealed almost 100% activity of the pgk promoter) was found to be several-fold higher than the LacZ titer ( Figure 2b ; and data not positivity for all bicistronic nlslacZ vectors, whereas nuclear ␤-galactosidase activity could be detected in shown). approximately 10% of MSCVnlslacZ-transduced G418-resistant PA317 cells. Based on staining intensity, Stable expression of transduced nlslacZ genes from bicistronic retroviral vectors in human melanoma cell MENVnlslacZ directed the highest levels of ␤-galactosidase activity among the MSCV-based bicistronic vectors lines We then assessed gene expression from the set of bicis-(data not shown). To examine nlslacZ expression in PA317 cells at the transcriptional level, total RNA was tronic retroviral vectors in WM9 and three other human melanoma cell lines (WM35, WM239 and WM902b) transisolated from the different retrovirus producer cell lines and subjected to Northern blot analysis using an nlslacZ duced with undiluted vector supernatants. Three days after transduction, X-gal staining demonstrated 20-60% probe (Figure 2a) . The levels of steady-state nlslacZ mRNA detected roughly correlated with ␤-galactosidase ␤-galactosidase-positive cells when MSCVnlslacZ, MINVnlslacZ, MENVnlslacZ and SAMENnlslacZ vector activity. In particular, significant levels of appropriately sized LTR-directed spliced transcripts were observed preparations were used, compared to 2-10% ␤-galactosidase-positive cells when DCCMVnlslacZ vector superfrom the MENVnlslacZ vector (comparable to those achieved with SAMENnlslacZ). Consistent with earlier work natant was applied. In general, WM902b cells tended to be the most efficiently transduced, followed by WM9 and evaluating expression of exogenous genes in PA317 cells from retroviral vectors containing different promoters, 40 WM239 cells, with the least numbers of ␤-galactosidasepositive cells being obtained for WM35 cells. When the the hCMV-IE promoter present in DCCMVnlslacZ was found to direct considerably lower levels of nlslacZ trantransduced cells were selected in G418 for 3 weeks and polyclonal populations were subjected to X-gal staining, scripts than the retroviral LTRs.
The effective titers of the bicistronic nlslacZ retrogreater than 90% ␤-galactosidase-positive cells were observed in all cases for the bicistronic vectors, with the viruses were determined by transduction of WM9 human melanoma cells with various dilutions of vector superhighest levels of ␤-galactosidase seen in DCCMVnlslacZtransduced cell lines (Figure 3 ). natants and enumeration of ␤-galactosidase-positive cells (see Materials and methods). As shown in Figure 2b , In contrast to the findings in PA317 cells, Northern blot analysis of steady-state nlslacZ mRNA levels in the panel except for DCCMVnlslacZ, the titer of which was up to 100-fold lower than the others, all vectors efficiently of stably transduced human melanoma cell lines revealed that the DCCMVnlslacZ vector reproducibly directed the transmitted functional ␤-galactosidase activity to WM9 highest levels (Figure 4 ). This result was in agreement with the X-gal staining showing that the highest amounts of ␤-galactosidase could be detected in cells transduced with this vector. Of note, the transcriptional activity of the MENVnlslacZ vector was significantly less than that of the MINVnlslacZ vector in all of the human melanoma cell lines. It was also noteworthy that, although relatively high levels of LTR-directed full-length transcripts were achieved with the MoMLV-based SAMENnlslacZ vector in the human melanoma cell lines, unlike PA317 cells where similar levels of full-length and spliced transcripts were found, much lower levels of spliced transcripts were observed (eg see Figure 4 , WM902b panel, lane 4). high levels of the hIL-6 and hsIL-6R genes in human melanoma cells. DCCMVhIL-6 and DCCMVhsIL-6R, containing the hCMV-IE-hIL-6-IRES-neo and hCMV-IE-hsILrange of 90-300 ng/ml/10 6 cells per 24 h, while hsIL-6R 6R-IRES-neo transcriptional units, respectively, in their 3′ levels ranged from 24-95 ng/ml/10 6 cells per 24 h. LTRs were therefore constructed, and recombinant amphotropic retroviral stocks prepared as before from PA317 packaging cells. These vector preparations were Discussion then used to transduce the WM9, WM35, WM239 and WM902b cell lines; after selection in G418, the expression
The concept of active immunotherapy of cancer is based on the premise that tumors possess antigens which can of vector-specific hIL-6 and hsIL-6R RNAs was examined in polyclonal populations by Northern blot analysis be recognized by the patient's immune system. Compelling data now indicate that tumor-associated antigens do (Figure 5a) . In all cases, DCCMVhIL-6-and DCCMVhsIL-6R-transduced melanoma cells expressed significant levindeed exist but tumors apparently evade host immune defenses by decreased, or lack of, cell surface expression els of the appropriate hCMV-IE promoter-initiated vector transcripts. The resultant double-copy structures of these of appropriate immunoregulatory or costimulatory molecules. The intent of genetic manipulation in cancer vectors were apparently more favorable for LTR-directed transcription than that harboring the hCMV-IE-nlslacZimmunotherapy, therefore, is to alter the tumor cell phenotype by expressing immunostimulatory proteins, IRES-neo transcriptional unit, since appreciably higher levels of LTR-driven RNA species were observed than thus invoking a systemic immune response against previously masked determinants on the antigens. 1,2 Maligseen in DCCMVnlslacZ-transduced cells.
The amounts of hIL-6 and hsIL-6R produced by the nant melanoma is particularly immunogenic among human tumors and the best characterized with respect to different transduced lines were investigated using specific immunoassays (see Materials and methods). As illusantigenic determinants recognized by cytolytic T cells.
11
While genetic modification of melanoma cells in situ to trated in Figure 5b , hIL-6 levels were found to be in the ferred at high frequency to the 5′ LTR in transduced target cells, satisfying the prediction of the original double-copy design that foreign sequences of this size could be tolerated (size constraints being the main limitation affecting the efficiency with which vector RNA containing a packaging signal is encapsidated into virions). 35 While the titers of DCCMV-type vectors were substantially reduced in comparison to the titers of the other bicistronic MSCV-based vectors tested having more conventional vector designs, as noted above, titer is not a critical factor with regard to the gene transfer applications intended for this class of vector, ie stable gene delivery to permanent cell lines. Although we did not quantify radioactivity of Northern blots by ␤-emission counting, nor normalize gene expression levels to proviral copy number, it is clear that the hCMV-IE promoter in the DCCMVnlslacZ vector consistently outperformed the MSCV and MoMLV LTRs in human melanoma cells. However, our data do not address the issue as to whether other vectors, such as MFG, 3 which use the retroviral LTR to express the gene of interest and utilize viral splice donor/acceptor sequences to achieve controlled splicing of vector transcripts, might direct higher levels of exogenous gene expression than the vectors studied. Unexpectedly, however, significant utilization of the splice 
acceptor sequence was not observed for the (a) Northern blot analysis of hIL-6 and shIL-6R transcripts in four mela-
SAMENnlslacZ vector, which is similar in design to noma cell lines transduced with the DCCMVhIL-6 and DCCMVhsIL-6R
MFG, 34 higher than genes expressed from MSCV and MINV, as the long 5′ untranslated region (corresponding to the extended packaging signal) which is situated upstream of the gene of interest in those vectors would be expected boost antitumor immunity is the ultimate goal, deficiencies in current in vivo gene delivery technologies to reduce translational efficiency somewhat.
42
The MSCV retroviral vector was originally designed to will need to be rectified before such strategies can be expected to have potential clinical utility. 5 On the other alleviate the transcriptional block experienced by MoMLV-based retroviral vectors in undifferentiated hand, production of individualized autologous genetransduced melanoma vaccines ex vivo is a labor-intencells. 15, 16 Transcriptional extinction has also been seen with MoMLV-based LTRs in vivo.
17, 18 The melanoma cell sive, time-consuming and costly endeavor. 4 Because shared melanoma antigens have been identified that are lines studied in this report harboring DCCMV proviruses have been maintained in continuous culture for over a recognized by cytolytic T cells present in a large majority of melanoma patients having common HLA haplotypes, year with no reduction in exogenous gene expression (unpublished observations). It remains to be determined a mixture of autologous tumor cells and previously characterized, genetically modified allogeneic melanoma though whether the in vivo permissiveness conferred by the MSCV LTR and the dl587rev virus tRNA primer bindcell lines as a vaccine provides a solution to this problem.
7-10 In order to identify the best retroviral vector for ing site (which is devoid of a MoMLV silencer element) will be compromised by the presence of the hCMV-IE this application, we comparatively analyzed several different bicistronic configurations and showed that the promoter. Besides cancer vaccines, it is envisioned that this particular design may have utility in tissue engineerhCMV-IE promoter-containing DCCMV vector, which combines the principles of double-copy and IRES vector ing applications where the intent is to implant polymer encapsulated cell lines genetically engineered to continudesigns, 21, 35 reproducibly directed high stable levels of exogenous gene expression in a panel of four human ously secrete pharmacological levels of bioactive proteins. 43 , 44 For such applications, it may be advantageous melanoma cell lines.
In the DCCMVnlslacZ double-copy bicistronic retrovito substitute the hCMV-IE promoter with tissue-specific cellular transcriptional regulatory elements. 45, 46 The speral vector, an approximately 5.7 kb insert was accommodated in the U3 region of the 3′ LTR and faithfully transcific double-copy bicistronic vector described in this study, DCCMV, confers G418 resistance. Analogs of this Construction of retroviral vectors and generation of producer cell lines vector containing other selectable marker genes can be The MINV retroviral vector was constructed from easily derived for sequential introduction of multiple MSCVneoEB and contains an EMCV IRES sequence (a genes into an individual cell line; in particular, a pac-congift from J Majors, Washington University, St Louis, MO, taining derivative, encoding resistance to puromycin, USA) in place of the pgk promoter. 27, 37 The SAMEN veccould be readily constructed by incorporation of the tor, based on the LN series of vectors, 22 is similar in IRES-pac cassette from the MIPV retroviral vector. 47 design to MINV except that it contains the splice acceptor Several phase I/II clinical trials investigating immunoof the env region upstream of the EMCV IRES-neo cassette therapy approaches to the treatment of malignant mela-(a gift from J Treisman and S Rosenberg, National Instinoma are underway, including a pilot vaccine study tutes of Health, Bethesda, MD, USA). 34 MENV was conusing allogeneic melanoma cells transduced with the structed by replacing all internal sequences in MSCV human IL-2 gene. 48, 49 We and others have demonstrated between SpeI (position 662) and BamHI (position 2750) significant antitumor effects of IL-6 in murine melanoma with the corresponding SpeI-BamHI SAMEN fragment models. 38, 50, 51 The finding by our group and other investicontaining the packaging signal, env splice donor, env gators that a complex of IL-6 and sIL-6R (a soluble form splice acceptor and the EMCV IRES-neo cassette. A 3.5-of the ligand binding chain of the IL-6 receptor) can kb fragment containing a modified LacZ gene (nlslacZ), stimulate a response by cells lacking membrane IL-6R but which codes for E. coli ␤-galactosidase fused to a 21-possessing the signal transducing gp130 component of amino acid nuclear localization sequence from Simian the receptor suggested the possibility that melanoma cells virus 40 large T antigen, was excised from the expressing sIL-6R in concert with IL-6 may exhibit pMG48nlslacZ vector (a gift from N Ferry, Institut Pastsuperior immunization potential. 39, 52 We subsequently eur, Paris, France) by BamHI digestion. 33 The ends of the showed in the B-78 murine melanoma model that a vacnlslacZ fragment were filled in by treatment with the cine consisting of IL-6/sIL-6R-transfected tumor cells Klenow fragment of E. coli DNA polymerase I and it was (constitutively secreting IL-6/sIL-6R in the range of 1-10 inserted into the filled XhoI site of the MSCVneoEB, ng/ml 10 6 cells per 24 h) was a more potent stimulator MINV, MENV and SAMEN vectors to form, respectively, of systemic antitumor immunity than vaccines consisting MSCVnlslacZ, MINVnlslacZ, MENVnlslacZ and of cells transfected with either gene alone. 38 A role of ILSAMENnlslacZ. The DCCMVnlslacZ vector was con-6 in the generation and activation of cytolytic T cells has structed in several steps from the double-copy retroviral been well demonstrated. 53 The potentiation of the cellular vector MDCV. 37 MDCV is essentially MSCVneoEB with antitumor immune response by sIL-6R may be due in a 48-bp polylinker containing unique ClaI, NruI, SacII and part to the stimulation of activated T cells, which do not MluI restriction sites downstream of the NheI restriction express functional IL-6 receptors, by the IL-6/sIL-6R site present in the U3 region of the 3′ LTR. The pgk-neo complex.
54 Based on these preclinical findings, we cassette in MDCV was first excised by digestion with designed a clinical vaccine strategy to treat HLA-A1-BglII and BamHI and the backbone self-ligated. Next, a and/or HLA-A2-positive melanoma patients whereby PstI fragment from the pKEX-2-XR plasmid, containing irradiated autologous tumor cells are admixed with the hCMV-IE gene promoter followed by a polylinker HLA-A1,A2-positive allogeneic melanoma cells geneti-(including BamHI and SalI restriction sites), was bluntcally engineered to secrete IL-6 and sIL-6R. 8 Because the end ligated into the NruI site. 36 A SalI-BamHI fragment double-copy bicistronic retroviral vectors DCCMVhIL-6 containing the EMCV IRES-neo cassette from MINV was and DCCMVhsIL-6R were found to direct the expression then blunt-end ligated into a filled MluI site in the of 10-30-fold higher levels of hIL-6/hsIL-6R in four difresulting plasmid. Finally, the 3.5-kb nlslacZ fragment ferent human melanoma cell lines (up to 300 and 100 was inserted into the BamHI site between the hCMV-IE ng/ml 10 6 cells per 24 h, respectively) than was required promoter and the EMCV IRES sequence. DCCMVhIL-6 for in vivo antitumor activity in the B-78 murine melaand DCCMVhsIL-6R were generated by inserting the noma model, such gene-modified melanoma cell lines human IL-6 or soluble IL-6R cDNAs, excised as SalI fragshould be suitable for use in our phase II clinical vacments from the pEXIL-6 and pEXSIRI expression vectors cine trial for the treatment of patients with stage III (kindly provided by S Rose-John, Mainz, Germany), strate at 32°C for 8 h to reveal nuclear ␤-galactosidase 
